October 28, 2021 -- MilliporeSigma has launched new technology to support efforts to double its antibody drug conjugate (ADC) and high-potent active pharmaceutical ingredient (HPAPI) capacity.
The company launched ChetoSensar to address the hydrophobicity of ADCs, the company said. Many ADC candidates have poor aqueous solubility; MilliporeSigma estimates that more than 20% of ADC clinical terminations are caused by this issue. ChetoSensar technology improves ADC solubility, the company said.
Millipore has also launched a new platform called Dolcore, which can increase the speed to market for dolostatin-based ADC payloads by up to a year, the company said.
In addition, the company will enhance the ADC capabilities of its clinical manufacturing facility in St. Louis, Missouri, in December. Last year, the company announced a $65 million expansion of its facility near Madison, WI, which it expects will double its HPAPI kilo lab capacity and enable the company to expedite the manufacture of HPAPIs, ADC linker/payloads, and complex APIs.
MilliporeSigma, the U.S. and Canadian life science business of Merck, has launched new technology and expanded its capacity to advance ADC therapies. Image courtesy of MilliporeSigma.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
